Seroprevalence of measles, mumps and rubella among young adults, after 20 years of universal 2-dose MMR vaccination in Israel

Figures & data

Table 1. Results of 4 measles IgG seroprevalence studies among young adults in Israel, by gender and year of recruitment

	Year	Sera tested	Negative N (%)	Equivoca lN (%)	Positive N (%)	95% CI of % positive	No. of Childhood Vaccinations (Age in M/Y)
Males	1987	250	35 (14.0)	34 (13.6)	181 (72.4)	66.9 – 77.9
	1990	239	NA	NA	202 (84.5)	79.3 – 88.9
	1996	339	18 (5.3)	4 (1.2)	317 (93.5)	90.3– 95.9
	2007	248	19 (7.7)	19 (7.7)	210 (84.7)	80.7 – 92.1
Females	1987	207	34 (16.4)	19 (9.2)	154 (74.4)	68.5 – 80.3
	1990	204	NA	NA	180 (88.2)	83.0 – 92.3
	1996	201	2 (1.0)	0 (0)	199 (99.0)	96.5– 99.9
	2007	191	7 (3.7)	18 (9.4)	166 (86.9)	81.3 – 91.4
Total	1987	457	69 (15.1)	53 (11.6)	335 (73.3)	69.2 – 77.4	1 (9 M)
	1990	443	NA	NA	382 (86.2)	82.8 – 89.2	1 (12 M)
	1996	540	20 (3.7)	4 (0.7)	516 (95.6)	93.5 – 97.1	2 (15 M, 13 Y)
	2007	439	26 (5.9)	37 (8.4)	376 (85.7)	82.0 – 88.8	2 (12 M, 6 Y)

¹ Data for 1987 from Danon et al.²⁴ Data for 1990 from Lerman et al.²⁷ Data for 1996 from Gdalevich et al.²⁸

² NA = Not applicable. Data was partial for 1990 sero-survey.

³ M = months, Y = years.

Table 2. Differences in proportion of measles IgG seroprevalence among young adults in Israel, by gender and year of recruitment (1987, 1990 and 1996 compared to 2007)

	Year	Absolute difference (%)	95% CI of difference (%)	P value (χ^2 test)
Males	1987 vs. 2007	−12.3	−19.4 – (−)5.2	0.001
	1990 vs. 2007	−0.2	−6.6 – 6.3	0.96
	1996 vs. 2007	8.8	3.6 – 14.0	<0.001
Females	1987 vs. 2007	−12.5	−20.2 – (−)4.9	0.002
	1990 vs. 2007	1.3	−5.2 – 7.8	0.69
	1996 vs. 2007	12.1	7.1 – 17.1	<0.001

Table 3. Prevalence of rubella and mumps IgG antibodies among young adults in Israel (N = 406), by measles IgG seropositivity (N, % of column)

	Measles seropositive	Measles equivocal	Measles seronegative	Total
Total	345 (100)	35 (100)	26 (100)	406 (100)
Positive to rubella and mumps	275 (79.7)	21 (60)	8 (30.8)	304 (74.9)
Positive to rubella, negative to mumps	37 (10.7)	6 (17.1)	9 (34.6)	52 (12.8)
Negative to rubella, positive to mumps	25 (7.3)	7 (20)	2 (7.7)	34 (8.4)
Negative to rubella and mumps	8 (2.3)	1(2.9)	7(26.9)	16 (3.9)

Danon Y, Adir Y, Abend I, Zaaide Y, Green M. Prevalence of antibodies against measles, mumps and rubella in Israeli young adults. Israel J Med Sci 1992; 28:733; PMID:1399506

 PubMedGoogle Scholar

Lermarn Y, Riskin-Mashiach S, Cohen D, Slepon R, Shohat T, Harari H, Wiener M, Danon YL. Immunity to measles in young adults in Israel. Infection 1993; 21:154-7; PMID:8365813; http://dx.doi.org/10.1007/BF01710534

 PubMedGoogle Scholar

Gdalevich M, Robin G, Mimouni D, Grotto I, Shpilberg O, Ashkenazi I. Measles antibody prevalence rates among young adults in Israel. Am J Infect Control 2002; 30:165-9; PMID:11988711; http://dx.doi.org/10.1067/mic.2002.118617

 PubMedGoogle Scholar